112 related articles for article (PubMed ID: 25420854)
1. Gastrointestinal disorders after renal transplantation.
Savvidaki E; Papachristou E; Kazakopoulos P; Papasotiriou M; Vardoulaki M; Goumenos DS
Transplant Proc; 2014 Nov; 46(9):3183-6. PubMed ID: 25420854
[TBL] [Abstract][Full Text] [Related]
2. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
[TBL] [Abstract][Full Text] [Related]
3. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
[TBL] [Abstract][Full Text] [Related]
4. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
Sterneck M; Settmacher U; Ganten T; Sarrazin C; Speidel N; Broering D; Heyne N; Paulus E; Mertens M; Fischer L
Transplant Proc; 2014; 46(1):234-40. PubMed ID: 24507058
[TBL] [Abstract][Full Text] [Related]
5. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
Lopez-Solis R; DeVera M; Steel J; Fedorek S; Sturdevant M; Hughes C; Humar A
Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
[TBL] [Abstract][Full Text] [Related]
8. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.
Kamar N; Oufroukhi L; Faure P; Ribes D; Cointault O; Lavayssiere L; Nogier MB; Esposito L; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Oct; 20(10):2231-6. PubMed ID: 16046517
[TBL] [Abstract][Full Text] [Related]
9. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.
Langone AJ; Chan L; Bolin P; Cooper M
Transplantation; 2011 Feb; 91(4):470-8. PubMed ID: 21245794
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
11. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bunnapradist S; Sampaio MS; Wilkinson AH; Pham PT; Huang E; Kuo HT; Anastasi B; Danovitch GM; Lo SK
Am J Nephrol; 2014; 40(2):184-90. PubMed ID: 25196230
[TBL] [Abstract][Full Text] [Related]
12. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
13. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
[TBL] [Abstract][Full Text] [Related]
15. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
Burg M; Säemann MD; Wieser C; Kramer S; Fischer W; Lhotta K
Transplant Proc; 2009 Dec; 41(10):4159-64. PubMed ID: 20005359
[TBL] [Abstract][Full Text] [Related]
16. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.
Bolin P; Tanriover B; Zibari GB; Lynn ML; Pirsch JD; Chan L; Cooper M; Langone AJ; Tomlanovich SJ
Transplantation; 2007 Dec; 84(11):1443-51. PubMed ID: 18091520
[TBL] [Abstract][Full Text] [Related]
17. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
[TBL] [Abstract][Full Text] [Related]
18. The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.
Martinez-Mier G; Salazar-Ramirez A
Transplant Proc; 2016 Mar; 48(2):588-95. PubMed ID: 27110009
[TBL] [Abstract][Full Text] [Related]
19. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
20. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]